SEHK:2315Biotechs
Biocytogen Pharmaceuticals Beijing Q1 Margin Expansion Reinforces Bullish Earnings Narratives
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) has opened Q1 2026 with revenue of ¥433.1 million and basic EPS of ¥0.23, against a backdrop of trailing twelve month revenue of about ¥1.6 billion and basic EPS of ¥0.72 that has been associated with very large year over year earnings expansion and a higher net margin of 18.6% versus 7.6% a year earlier. Over recent periods, revenue has moved from ¥980.5 million on a trailing basis in Q4 2024 to ¥1.6 billion by Q1 2026, while quarterly EPS has...